Medium Risk

RPG Life Sciences Limited

Manufacturing and marketing of pharmaceutical products

CIN: L24232MH2007PLC169354 FY: - Revenue: ₹653.4 Cr
5.5
ESG Risk
Score /10
Compliance RiskEpr ExposureGhg Intensity

Risk Breakdown

GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.0
EPR Exposure
6.5
Compliance Risk
10.0
HR Risk
5.0
Governance Risk
5.0

Financial Exposure

Est. Compliance Cost₹1–4 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated192.0 T

Governance

Anti-Corruption PolicyYes
Conflict of Interest PolicyUnknown
BRSR AssuranceNone
Assurance Provider

Double Materiality

Financial Materiality5.5
Impact Materiality5.1
QuadrantDual Materiality

Supply Chain

MSME Sourcing0.2%
Lifecycle AssessmentNo
Product ReclaimYes

Material Risks

e-waste

ESG Targets & Commitments

TopicTarget / MetricStatus
Human Rights in Supply Chain HR clauses in all contracts Commitment

AI Risk Summary

**RPG Life Sciences Limited – Financial Risk Summary** RPG Life Sciences faces a critical compliance exposure of ₹1–4 crore annually under SEBI BRSR Core Expansion mandates, with a maximum compliance risk score of 10.0/10 posing delisting or enforcement action risk if disclosure and environmental reporting obligations are not met. The company's EPR (Extended Producer Responsibility) exposure of 6.5/10 remains unresolved—unknown applicability across pharmaceutical product categories creates contingent liability risk, as mandatory EPR compliance under Plastic Waste Management Rules 2021 could trigger significant operational costs. Notably, the absence of reported Scope 1 and Scope 2 emissions data (despite manufacturing operations) suggests measurement gaps rather than zero impact; this disclosure failure directly violates BRSR P6 requirements and increases regulatory scrutiny likelihood. With medium ESG risk (5.5/10) driven primarily by compliance gaps, the company must immediately quantify emissions, clarify EPR obligations, and establish robust environmental management reporting to mitigate ₹1–4 crore compliance costs and regulatory penalties.

Source: RPG Life Sciences Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.

← Back to ESG Quotient Dashboard Share on LinkedIn Browse all companies →